Tectorigenin ameliorated high-fat diet-induced nonalcoholic fatty liver disease through anti-inflammation and modulating gut microbiota in mice

Duan, Ruiqian; Huang, Kai; Guan, Xiao; Li, Sen; Xia, Jian Chuan; Shen, Meng; Sun, Zhi‐Wei; Yu, Zhiquan

doi:10.1016/j.fct.2022.112948

Cited by 36 publications

(21 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Lachnospiraceae_UCG-006 was also reduced in the pioglitazone monotherapy group. It was found highly potentially associated with diet-induced obesity and nonalcoholic fatty liver disease-related parameters in serum and liver in previous studies (Li et al, 2020;Duan et al, 2022). In addition, several beneficial microbes, such as Candidatus_Soleaferrea, were increased in pioglitazone monotherapy group (Zou et al, 2022).…”

Section: Discussionmentioning

confidence: 90%

“…Parasutterella was identified as a core component of the gut microbiota in humans and mice and is associated with various health outcomes in bile acid profiles and cholesterol metabolism ( Ju et al, 2019 ). Conversely, several harmful microbes were reduced, such as Oscillibacter, Eubacterium_xylanophilum_group and Lachnospiraceae _UCG-006 ( Kong et al, 2019 ; Li et al, 2020 ; Duan et al, 2022 ; Peng et al, 2022 ). Therefore, the alterations of these beneficial and harmful microbes indicate significant synergistic effects of combination therapy on gut microbiota modification.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Potential benefits of metformin and pioglitazone combination therapy via gut microbiota and metabolites in high-fat diet-fed mice

et al. 2022

View full text Add to dashboard Cite

Metformin and pioglitazone monotherapy have been proven to alter gut microbiota in diabetes and obesity. The present study aimed to investigated whether the combined administration of pioglitazone and metformin achieved superior protective effects on high-fat diet (HFD)-fed obese mice and elucidated its molecular mechanism via the gut microbiota and its metabolites. C57BL/6 males were randomly divided into five groups: the control group, fed a normal control diet; the HFD group, fed an HFD; the metformin monotherapy group, fed an HFD and treated with metformin; the pioglitazone monotherapy group, fed an HFD and treated with pioglitazone; and the combination therapy group, fed an HFD and treated with metformin and pioglitazone combination therapy. The cecal contents were collected for 16S rDNA amplicon sequencing and untargeted metabolomics analysis. The results showed that the combination therapy of metformin and pioglitazone significantly improved insulin sensitivity and glucolipid metabolism in HFD-fed mice. Combination therapy markedly altered gut microbiota by increasing beneficial bacteria, such as Bifidobacterium, Christensenellaceae_R-7_group, Faecalibacterium and Roseburia, and decreasing harmful bacteria, such as Oscillibacter and Eubacterium_xylanophilum_group. Fecal metabolites were significantly changed in the combination therapy group, including a reduction in amino acid metabolism and augmentation of lipid metabolism, such as citrulline, sarcosine, D-glutamine, lipoxin A4, prostaglandin E2, stearidonic acid and lucidenic acid A. These results revealed that combined metformin and pioglitazone therapy had synergistic effects or at least have an additive effect on modifying gut microbiota and metabolites, closely associated with improved glucolipid metabolic parameters in HFD-fed mice, which provides novel evidence and promising targets for metformin and pioglitazone combination therapy in type 2 diabetes.

show abstract

Section: Discussionmentioning

confidence: 90%

Section: Discussionmentioning

confidence: 99%

Potential benefits of metformin and pioglitazone combination therapy via gut microbiota and metabolites in high-fat diet-fed mice

et al. 2022

View full text Add to dashboard Cite

show abstract

“…We also applied fecal microbiome sequencing to identify changes in the microbiota and found that Lachnoclostridium, norank_o:Clostridia_UCG014 and Roseburia were higher in the gut of mice during acute liver injury, whereas Bacteroides and Akkermansiacea were lower in the acute liver injury group. Among these, Lachnoclostridium has been found to be significantly more abundant in the gut of high-fat diet rats ( 31 , 32 ) but was significantly inhibited after our treatment. Roseburia has also been shown to increase in abundance in high-fat diet mice and has been found to be positively correlated with increased deoxycholic acid in the plasma, liver tissue, and feces of high-fat diet mice as well ( 33 ).…”

Section: Discussionmentioning

confidence: 79%

The effects of rhein on D-GalN/LPS-induced acute liver injury in mice: Results from gut microbiome-metabolomics and host transcriptome analysis

Liu

Yin²,

Yang³

et al. 2022

Front. Immunol.

View full text Add to dashboard Cite

BackgroundRhubarb is an important traditional Chinese medicine, and rhein is one of its most important active ingredients. Studies have found that rhein can improve ulcerative colitis by regulating gut microbes, but there are few reports on its effects on liver diseases. Therefore, this study aims to investigate these effects and underlying mechanisms.MethodsMice were given rhein (100 mg/kg), with both a normal control group and a model group receiving the same amount of normal saline for one week. Acute liver injury was induced in mice by intraperitoneal injection of D-GalN (800 mg/kg)/LPS (10 ug/kg). Samples (blood, liver, and stool) were then collected and assessed for histological lesions and used for 16S rRNA gene sequencing, high-performance liquid chromatography-mass spectrometry (LC-MS) and RNA-seq analysis.ResultsThe levels of ALT and AST in the Model group were abnormal higher compared to the normal control group, and the levels of ALT and AST were significantly relieved in the rhein group. Hepatic HE staining showed that the degree of liver injury in the rhein group was lighter than that in the model group, and microbiological results showed that norank_o:Clostridia_UCG-014, Lachnoclostridium, and Roseburia were more abundant in the model group compared to the normal control group. Notably, the rhein treatment group showed reshaped disturbance of intestinal microbial community by D-GalN/LPS and these mice also had higher levels of Verrucomicrobia, Akkermansiaceae and Bacteroidetes. Additionally, There were multiple metabolites that were significantly different between the normal control group and the model group, such as L-α-amino acid, ofloxacin-N-oxide, 1-hydroxy-1,3-diphenylpropan-2-one,and L-4-hydroxyglutamate semialdehyde, but that returned to normal levels after rhein treatment. The gene expression level in the model group also changed significantly, various genes such as Cxcl2, S100a9, Tnf, Ereg, and IL-10 were up-regulated, while Mfsd2a and Bhlhe41 were down-regulated, which were recovered after rhein treatment.ConclusionOverall, our results show that rhein alleviated D-GalN/LPS-induced acute liver injury in mice. It may help modulate gut microbiota in mice, thereby changing metabolism in the intestine. Meanwhile, rhein also may help regulate genes expression level to alleviate D-GalN/LPS-induced acute liver injury.

show abstract

“…SCFAs maintained intestinal barrier function and reduced lipopolysaccharides content in blood, thereby helping to reduce systemic inflammation and reverse insulin resistance ( 45 ). In obese mice, increased levels of Lachnospiraceae _UCG-006 were found to regulate the gut microbiota and improve glucose metabolism disorders ( 46 ). Dubosiella can alleviate gut disorders caused by HFD but many studies have found members of this genera to be detrimental; so, further studies are needed to fully elucidate its role in the human gut ( 47 ).…”

Section: Discussionmentioning

confidence: 99%

Pear pomace soluble dietary fiber ameliorates the negative effects of high-fat diet in mice by regulating the gut microbiota and associated metabolites

Mao

Gao

et al. 2022

Front. Nutr.

View full text Add to dashboard Cite

The gut microbiota and related metabolites are positively regulated by soluble dietary fiber (SDF). In this study, we explored the effects of SDF from pear pomace (PP) on the regulation of gut microbiota and metabolism in high-fat-diet-fed (HFD-fed) C57BL/6J male mice. The results showed that PP-SDF was able to maintain the HFD disrupted gut microbiota diversity with a significant increase in Lachnospiraceae_UCG-006, Akkermansia, and Bifidobacterium spp. The negative effects of high-fat diet were ameliorated by PP-SDF by regulating lipid metabolisms with a significant increase in metabolites like isobutyryl carnitine and dioscoretine. Correlation analysis revealed that gut microbiota, such as Akkermansia and Lachnospiraceae_UCG-006 in the PP-SDF intervention groups had strong positive correlations with isobutyryl carnitine and dioscoretin. These findings demonstrated that PP-SDF interfered with the host's gut microbiota and related metabolites to reduce the negative effects caused by a high-fat diet.

show abstract

Tectorigenin ameliorated high-fat diet-induced nonalcoholic fatty liver disease through anti-inflammation and modulating gut microbiota in mice

Cited by 36 publications

References 50 publications

Potential benefits of metformin and pioglitazone combination therapy via gut microbiota and metabolites in high-fat diet-fed mice

Potential benefits of metformin and pioglitazone combination therapy via gut microbiota and metabolites in high-fat diet-fed mice

The effects of rhein on D-GalN/LPS-induced acute liver injury in mice: Results from gut microbiome-metabolomics and host transcriptome analysis

Pear pomace soluble dietary fiber ameliorates the negative effects of high-fat diet in mice by regulating the gut microbiota and associated metabolites

Contact Info

Product

Resources

About